This case demonstrates myTAP’s efficacy—via chair-side titration—for rapid OSA relief in denial-prone patients, with mouth shielding amplifying benefits at minimal advancement. Step-wise PSG at fixed edge-to-edge position shows nasal enforcement resolving residual apneas, desaturations, and sympathetic overdrive beyond protrusion alone, highlighting TAP appliances’ market advantage.
Findings refute nasal/oral airflow equivalence, as in full-face CPAP. Nasal receptors maintain rhythmicity; anesthesia quadruples apneas, mimicking obstruction. Variable obstruction disrupts more than fixed, correlating with AHI via flow limitation and pharyngeal instability. Nasal breathing boosts nitric oxide, reduces resistance, and balances ANS/vagal tone.